Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges
Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...
Truist raises Exelixis stock target to $43 on Zanza optimism
Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...
Exelixis: Hold Rating Maintained Amidst Comparable Efficacy and Risks of Zanza and Cabo
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...
Promising Outlook for Exelixis’s Zanza: Strong Trial Results and Financial Prospects Support Buy Rating
Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00.Invest with ...
cweb14d
Exelixis’ Price Target Raised at Truist, Shares Rise 2 percent
Exelixis (NASDAQ:EXEL) shares rose more than 2% intra-day today after Truist Securities analysts increased their price target on the stock to $42, up from $38, while reaffirming a Buy rating. The move ...